{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:54:38Z","timestamp":1783828478999,"version":"3.55.0"},"publisher-location":"New York, NY","reference-count":167,"publisher":"Springer New York","isbn-type":[{"value":"9781493998135","type":"print"},{"value":"9781493998142","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-1-4939-9814-2_2","type":"book-chapter","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:43:49Z","timestamp":1571168629000},"page":"31-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology"],"prefix":"10.1007","author":[{"given":"Kerrie J.","family":"Sandgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi R.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstie","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony L.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"2_CR1","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1128\/AAC.01114-13","volume":"57","author":"JT Schiffer","year":"2013","unstructured":"Schiffer JT, Swan D, Corey L et al (2013) Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current Herpes Simplex Virus-2 directed antiviral agents. Antimicrob Agents Chemother 57:5820\u20135829. https:\/\/doi.org\/10.1128\/AAC.01114-13","journal-title":"Antimicrob Agents Chemother"},{"key":"2_CR2","doi-asserted-by":"publisher","unstructured":"Gottlieb SL, Giersing BK, Hickling J et al (2017) Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.084","DOI":"10.1016\/j.vaccine.2017.10.084"},{"key":"2_CR3","unstructured":"2011\u20132020 GVAP (2012) Global vaccine action plan 2011\u20132020 [online]. https:\/\/www.who.int\/immunization\/global_vaccine_action_plan\/GVAP_doc_2011_2020\/en\/"},{"issue":"1","key":"2_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","volume":"20","author":"EE Freeman","year":"2006","unstructured":"Freeman EE, Weiss HA, Glynn JR et al (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20(1):73\u201383","journal-title":"AIDS"},{"issue":"12","key":"2_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/s1473-3099(17)30405-x","volume":"17","author":"KJ Looker","year":"2017","unstructured":"Looker KJ, Elmes JAR, Gottlieb SL et al (2017) Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis 17(12):1303\u20131316. https:\/\/doi.org\/10.1016\/s1473-3099(17)30405-x","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/infdis\/jiy178","volume":"218","author":"J Bradley","year":"2018","unstructured":"Bradley J, Floyd S, Piwowar-Manning E et al (2018) Sexually transmitted bedfellows: exquisite association between HIV and herpes simplex virus type 2 in 21 communities in southern Africa in the HIV prevention trials network 071 (PopART) study. J Infect Dis 218(3):443\u2013452. https:\/\/doi.org\/10.1093\/infdis\/jiy178","journal-title":"J Infect Dis"},{"issue":"1","key":"2_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1086\/338231","volume":"185","author":"A Wald","year":"2002","unstructured":"Wald A, Link K (2002) Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185(1):45\u201352. https:\/\/doi.org\/10.1086\/338231","journal-title":"J Infect Dis"},{"issue":"5","key":"2_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/sextrans-2017-053336","volume":"94","author":"R Omori","year":"2018","unstructured":"Omori R, Nagelkerke N, Abu-Raddad LJ (2018) HIV and herpes simplex virus type 2 epidemiological synergy: misguided observational evidence? A modelling study. Sex Transm Infect 94(5):372\u2013376. https:\/\/doi.org\/10.1136\/sextrans-2017-053336","journal-title":"Sex Transm Infect"},{"issue":"10","key":"2_CR9","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1086\/368357","volume":"187","author":"SJ Reynolds","year":"2003","unstructured":"Reynolds SJ, Risbud AR, Shepherd ME et al (2003) Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 187(10):1513\u20131521. https:\/\/doi.org\/10.1086\/368357","journal-title":"J Infect Dis"},{"key":"2_CR10","doi-asserted-by":"publisher","unstructured":"Spicknall IH, Looker KJ, Gottlieb SL et al (2018) Review of mathematical models of HSV-2 vaccination: implications for vaccine development. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2018.02.067","DOI":"10.1016\/j.vaccine.2018.02.067"},{"issue":"4","key":"2_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.282.4.331","volume":"282","author":"L Corey","year":"1999","unstructured":"Corey L, Langenberg AG, Ashley R et al (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282(4):331\u2013340","journal-title":"JAMA"},{"issue":"21","key":"2_CR12","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1056\/NEJMoa011915","volume":"347","author":"LR Stanberry","year":"2002","unstructured":"Stanberry LR, Spruance SL, Cunningham AL et al (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347(21):1652\u20131661. https:\/\/doi.org\/10.1056\/NEJMoa011915","journal-title":"N Engl J Med"},{"key":"2_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1099\/0022-1317-79-2-353","volume":"79","author":"Z Mikloska","year":"1998","unstructured":"Mikloska Z, Cunningham AL (1998) Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 79. (Pt 2:353\u2013361","journal-title":"J Gen Virol"},{"issue":"1","key":"2_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa1103151","volume":"366","author":"RB Belshe","year":"2012","unstructured":"Belshe RB, Leone PA, Bernstein DI et al (2012) Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366(1):34\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1103151","journal-title":"N Engl J Med"},{"issue":"16","key":"2_CR15","doi-asserted-by":"publisher","first-page":"8206","DOI":"10.1128\/jvi.01302-15","volume":"89","author":"SL Lamers","year":"2015","unstructured":"Lamers SL, Newman RM, Laeyendecker O et al (2015) Global diversity within and between human herpesvirus 1 and 2 glycoproteins. J Virol 89(16):8206\u20138218. https:\/\/doi.org\/10.1128\/jvi.01302-15","journal-title":"J Virol"},{"issue":"6","key":"2_CR16","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/infdis\/jit651","volume":"209","author":"RB Belshe","year":"2014","unstructured":"Belshe RB, Heineman TC, Bernstein DI et al (2014) Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis 209(6):828\u2013836. https:\/\/doi.org\/10.1093\/infdis\/jit651","journal-title":"J Infect Dis"},{"issue":"4","key":"2_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121518","volume":"10","author":"MC Bernard","year":"2015","unstructured":"Bernard MC, Barban V, Pradezynski F et al (2015) Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs. PLoS One 10(4):e0121518. https:\/\/doi.org\/10.1371\/journal.pone.0121518","journal-title":"PLoS One"},{"issue":"22","key":"2_CR18","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352(22):2271\u20132284. https:\/\/doi.org\/10.1056\/NEJMoa051016","journal-title":"N Engl J Med"},{"issue":"6","key":"2_CR19","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","volume":"60","author":"VA Morrison","year":"2015","unstructured":"Morrison VA, Johnson GR, Schmader KE et al (2015) Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 60(6):900\u2013909. https:\/\/doi.org\/10.1093\/cid\/ciu918","journal-title":"Clin Infect Dis"},{"key":"2_CR20","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","volume":"217","author":"AL Cunningham","year":"2018","unstructured":"Cunningham AL, Heineman TC, Lal H et al (2018) Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged >\/=50 years. J Infect Dis 217:1750. https:\/\/doi.org\/10.1093\/infdis\/jiy095","journal-title":"J Infect Dis"},{"issue":"22","key":"2_CR21","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372(22):2087\u20132096. https:\/\/doi.org\/10.1056\/NEJMoa1501184","journal-title":"N Engl J Med"},{"issue":"6","key":"2_CR22","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","volume":"14","author":"TF Schwarz","year":"2018","unstructured":"Schwarz TF, Volpe S, Catteau G et al (2018) Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 14(6):1370\u20131377. https:\/\/doi.org\/10.1080\/21645515.2018.1442162","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"2_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent AM, Laupeze B, Di Pasquale A et al (2017) Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines 16(1):55\u201363. https:\/\/doi.org\/10.1080\/14760584.2016.1213632","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"2_CR24","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/infdis\/jis497","volume":"206","author":"I Leroux-Roels","year":"2012","unstructured":"Leroux-Roels I, Leroux-Roels G, Clement F et al (2012) A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 206(8):1280\u20131290. https:\/\/doi.org\/10.1093\/infdis\/jis497","journal-title":"J Infect Dis"},{"issue":"Suppl_2","key":"2_CR25","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/infdis\/jiy383","volume":"218","author":"A Weinberg","year":"2018","unstructured":"Weinberg A, Kroehl ME, Johnson MJ et al (2018) Comparative immune responses to licensed herpes zoster vaccines. J Infect Dis 218(Suppl_2):S81\u2013S87. https:\/\/doi.org\/10.1093\/infdis\/jiy383","journal-title":"J Infect Dis"},{"issue":"10","key":"2_CR26","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1172\/jci121484","volume":"128","author":"MJ Levin","year":"2018","unstructured":"Levin MJ, Kroehl ME, Johnson MJ et al (2018) Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest 128(10):4429\u20134440. https:\/\/doi.org\/10.1172\/jci121484","journal-title":"J Clin Invest"},{"issue":"1","key":"2_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/infdis\/173.1.7","volume":"173","author":"Z Mikloska","year":"1996","unstructured":"Mikloska Z, Kesson AM, Penfold ME et al (1996) Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-gamma. J Infect Dis 173(1):7\u201317","journal-title":"J Infect Dis"},{"key":"2_CR28","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1017\/CBO9780511545313","volume-title":"Human herpesviruses: biology, therapy, and immunoprophylaxis","author":"A Arvin","year":"2007","unstructured":"Arvin A, Abendroth A (2007) VZV: immunobiology and host response. In: Arvin A, Campadelli-Fiume G, Mocarski E et al (eds) Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, p 2007"},{"issue":"6","key":"2_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/rmv.478","volume":"15","author":"I Mori","year":"2005","unstructured":"Mori I, Nishiyama Y (2005) Herpes simplex virus and varicella-zoster virus: why do these human alphaherpesviruses behave so differently from one another? Rev Med Virol 15(6):393\u2013406. https:\/\/doi.org\/10.1002\/rmv.478","journal-title":"Rev Med Virol"},{"key":"2_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev.med.59.061606.095540","volume":"59","author":"DM Koelle","year":"2008","unstructured":"Koelle DM, Corey L (2008) Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 59:381\u2013395. https:\/\/doi.org\/10.1146\/annurev.med.59.061606.095540","journal-title":"Annu Rev Med"},{"issue":"10","key":"2_CR31","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/ni.2680","volume":"14","author":"WR Heath","year":"2013","unstructured":"Heath WR, Carbone FR (2013) The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol 14(10):978\u2013985. https:\/\/doi.org\/10.1038\/ni.2680","journal-title":"Nat Immunol"},{"issue":"3","key":"2_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/1568010054022033","volume":"4","author":"C Albanesi","year":"2005","unstructured":"Albanesi C, Scarponi C, Giustizieri ML et al (2005) Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy 4(3):329\u2013334","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"2","key":"2_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2012.12.1563","volume":"131","author":"IH Kuo","year":"2013","unstructured":"Kuo IH, Yoshida T, De Benedetto A et al (2013) The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol 131(2):266\u2013278. https:\/\/doi.org\/10.1016\/j.jaci.2012.12.1563","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2_CR34","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jid.2015.12.022","volume":"136","author":"GE Strittmatter","year":"2016","unstructured":"Strittmatter GE, Sand J, Sauter M et al (2016) IFN-gamma primes keratinocytes for HSV-1-induced inflammasome activation. J Invest Dermatol 136(3):610\u2013620. https:\/\/doi.org\/10.1016\/j.jid.2015.12.022","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2_CR35","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jid.2016.01.030","volume":"136","author":"R Aoki","year":"2016","unstructured":"Aoki R, Kawamura T, Goshima F et al (2016) The Alarmin IL-33 derived from HSV-2-infected keratinocytes triggers mast cell-mediated antiviral innate immunity. J Invest Dermatol 136(6):1290\u20131292. https:\/\/doi.org\/10.1016\/j.jid.2016.01.030","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2_CR36","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1172\/jci113908","volume":"83","author":"AL Cunningham","year":"1989","unstructured":"Cunningham AL, Noble JR (1989) Role of keratinocytes in human recurrent herpetic lesions. Ability to present herpes simplex virus antigen and act as targets for T lymphocyte cytotoxicity in vitro. J Clin Invest 83(2):490\u2013496. https:\/\/doi.org\/10.1172\/jci113908","journal-title":"J Clin Invest"},{"issue":"10","key":"2_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/0167-5699(94)90190-2","volume":"15","author":"BJ Nickoloff","year":"1994","unstructured":"Nickoloff BJ, Turka LA (1994) Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol Today 15(10):464\u2013469. https:\/\/doi.org\/10.1016\/0167-5699(94)90190-2","journal-title":"Immunol Today"},{"issue":"6","key":"2_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1462-5822.2006.00716.x","volume":"8","author":"A Takaoka","year":"2006","unstructured":"Takaoka A, Yanai H (2006) Interferon signalling network in innate defence. Cell Microbiol 8(6):907\u2013922. https:\/\/doi.org\/10.1111\/j.1462-5822.2006.00716.x","journal-title":"Cell Microbiol"},{"issue":"2","key":"2_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jri.2011.01.001","volume":"88","author":"T Chan","year":"2011","unstructured":"Chan T, Barra NG, Lee AJ et al (2011) Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa. J Reprod Immunol 88(2):210\u2013218. https:\/\/doi.org\/10.1016\/j.jri.2011.01.001","journal-title":"J Reprod Immunol"},{"issue":"4","key":"2_CR40","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1128\/jvi.01578-08","volume":"83","author":"H Donaghy","year":"2009","unstructured":"Donaghy H, Bosnjak L, Harman AN et al (2009) Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection. J Virol 83(4):1952\u20131961. https:\/\/doi.org\/10.1128\/jvi.01578-08","journal-title":"J Virol"},{"issue":"18","key":"2_CR41","doi-asserted-by":"publisher","first-page":"10168","DOI":"10.1128\/JVI.77.18.10168-10171.2003","volume":"77","author":"AA Ashkar","year":"2003","unstructured":"Ashkar AA, Rosenthal KL (2003) Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol 77(18):10168\u201310171","journal-title":"J Virol"},{"issue":"3","key":"2_CR42","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jaci.2016.06.034","volume":"139","author":"Y Kawakami","year":"2017","unstructured":"Kawakami Y, Ando T, Lee JR et al (2017) Defective natural killer cell activity in a mouse model of eczema herpeticum. J Allergy Clin Immunol 139(3):997\u20131006.e1010. https:\/\/doi.org\/10.1016\/j.jaci.2016.06.034","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"2_CR43","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1128\/jvi.02626-06","volume":"81","author":"M Thapa","year":"2007","unstructured":"Thapa M, Kuziel WA, Carr DJ (2007) Susceptibility of CCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization. J Virol 81(8):3704\u20133713. https:\/\/doi.org\/10.1128\/jvi.02626-06","journal-title":"J Virol"},{"issue":"26","key":"2_CR44","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/nejm198906293202605","volume":"320","author":"CA Biron","year":"1989","unstructured":"Biron CA, Byron KS, Sullivan JL (1989) Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320(26):1731\u20131735. https:\/\/doi.org\/10.1056\/nejm198906293202605","journal-title":"N Engl J Med"},{"issue":"4","key":"2_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jcv.2003.11.014","volume":"30","author":"A Dalloul","year":"2004","unstructured":"Dalloul A, Oksenhendler E, Chosidow O et al (2004) Severe herpes virus (HSV-2) infection in two patients with myelodysplasia and undetectable NK cells and plasmacytoid dendritic cells in the blood. J Clin Virol 30(4):329\u2013336. https:\/\/doi.org\/10.1016\/j.jcv.2003.11.014","journal-title":"J Clin Virol"},{"issue":"9","key":"2_CR46","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.1128\/JVI.72.9.7476-7483.1998","volume":"72","author":"DM Koelle","year":"1998","unstructured":"Koelle DM, Frank JM, Johnson ML et al (1998) Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol 72(9):7476\u20137483","journal-title":"J Virol"},{"issue":"9","key":"2_CR47","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.4049\/jimmunol.1103450","volume":"188","author":"M Kim","year":"2012","unstructured":"Kim M, Osborne NR, Zeng W et al (2012) Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4 T lymphocytes. J Immunol 188(9):4158\u20134170. https:\/\/doi.org\/10.4049\/jimmunol.1103450","journal-title":"J Immunol"},{"issue":"1","key":"2_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1006\/viro.1997.8441","volume":"229","author":"GN Milligan","year":"1997","unstructured":"Milligan GN, Bernstein DI (1997) Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229(1):259\u2013268. https:\/\/doi.org\/10.1006\/viro.1997.8441","journal-title":"Virology"},{"issue":"2","key":"2_CR49","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1128\/jvi.01282-08","volume":"83","author":"N Gill","year":"2009","unstructured":"Gill N, Ashkar AA (2009) Overexpression of interleukin-15 compromises CD4-dependent adaptive immune responses against herpes simplex virus 2. J Virol 83(2):918\u2013926. https:\/\/doi.org\/10.1128\/jvi.01282-08","journal-title":"J Virol"},{"issue":"1","key":"2_CR50","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1172\/jci111678","volume":"75","author":"AL Cunningham","year":"1985","unstructured":"Cunningham AL, Turner RR, Miller AC et al (1985) Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest 75(1):226\u2013233. https:\/\/doi.org\/10.1172\/jci111678","journal-title":"J Clin Invest"},{"issue":"6237","key":"2_CR51","doi-asserted-by":"publisher","first-page":"aaa6566","DOI":"10.1126\/science.aaa6566","volume":"348","author":"G Eberl","year":"2015","unstructured":"Eberl G, Colonna M, Di Santo JP et al (2015) Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. Science 348(6237):aaa6566. https:\/\/doi.org\/10.1126\/science.aaa6566","journal-title":"Science"},{"key":"2_CR52","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.coi.2016.01.006","volume":"39","author":"Q Yang","year":"2016","unstructured":"Yang Q, Bhandoola A (2016) The development of adult innate lymphoid cells. Curr Opin Immunol 39:114\u2013120. https:\/\/doi.org\/10.1016\/j.coi.2016.01.006","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"2_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/infdis\/170.1.20","volume":"170","author":"RL Ashley","year":"1994","unstructured":"Ashley RL, Corey L, Dalessio J et al (1994) Protein-specific cervical antibody responses to primary genital herpes simplex virus type 2 infections. J Infect Dis 170(1):20\u201326","journal-title":"J Infect Dis"},{"issue":"5","key":"2_CR54","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/515286","volume":"177","author":"WS Gallichan","year":"1998","unstructured":"Gallichan WS, Rosenthal KL (1998) Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis 177(5):1155\u20131161","journal-title":"J Infect Dis"},{"issue":"11","key":"2_CR55","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1128\/JVI.71.11.8109-8115.1997","volume":"71","author":"EL Parr","year":"1997","unstructured":"Parr EL, Parr MB (1997) Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J Virol 71(11):8109\u20138115","journal-title":"J Virol"},{"issue":"12","key":"2_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145228","volume":"10","author":"WP Halford","year":"2015","unstructured":"Halford WP, Geltz J, Messer RJ et al (2015) Antibodies are required for complete vaccine-induced protection against herpes simplex virus 2. PLoS One 10(12):e0145228. https:\/\/doi.org\/10.1371\/journal.pone.0145228","journal-title":"PLoS One"},{"issue":"6","key":"2_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065523","volume":"8","author":"WP Halford","year":"2013","unstructured":"Halford WP, Geltz J, Gershburg E (2013) Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2. PLoS One 8(6):e65523. https:\/\/doi.org\/10.1371\/journal.pone.0065523","journal-title":"PLoS One"},{"issue":"Pt 7","key":"2_CR58","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1099\/0022-1317-71-7-1497","volume":"71","author":"MR McDermott","year":"1990","unstructured":"McDermott MR, Brais LJ, Evelegh MJ (1990) Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2. J Gen Virol 71(Pt 7):1497\u20131504. https:\/\/doi.org\/10.1099\/0022-1317-71-7-1497","journal-title":"J Gen Virol"},{"issue":"3","key":"2_CR59","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1128\/jvi.75.3.1195-1204.2001","volume":"75","author":"LA Morrison","year":"2001","unstructured":"Morrison LA, Zhu L, Thebeau LG (2001) Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J Virol 75(3):1195\u20131204. https:\/\/doi.org\/10.1128\/jvi.75.3.1195-1204.2001","journal-title":"J Virol"},{"issue":"2","key":"2_CR60","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1006\/viro.2000.0298","volume":"270","author":"KL Dudley","year":"2000","unstructured":"Dudley KL, Bourne N, Milligan GN (2000) Immune protection against HSV-2 in B-cell-deficient mice. Virology 270(2):454\u2013463. https:\/\/doi.org\/10.1006\/viro.2000.0298","journal-title":"Virology"},{"issue":"Pt 4","key":"2_CR61","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1099\/0022-1317-82-4-845","volume":"82","author":"AM Harandi","year":"2001","unstructured":"Harandi AM, Svennerholm B, Holmgren J et al (2001) Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J Gen Virol 82(Pt 4):845\u2013853. https:\/\/doi.org\/10.1099\/0022-1317-82-4-845","journal-title":"J Gen Virol"},{"issue":"1","key":"2_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006141","volume":"13","author":"S Awasthi","year":"2017","unstructured":"Awasthi S, Hook LM, Shaw CE et al (2017) An HSV-2 trivalent vaccine is immunogenic in rhesus macaques and highly efficacious in guinea pigs. PLoS Pathog 13(1):e1006141. https:\/\/doi.org\/10.1371\/journal.ppat.1006141","journal-title":"PLoS Pathog"},{"issue":"12","key":"2_CR63","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1080\/21645515.2017.1323604","volume":"13","author":"S Awasthi","year":"2017","unstructured":"Awasthi S, Hook LM, Shaw CE et al (2017) A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model. Hum Vaccin Immunother 13(12):2785\u20132793. https:\/\/doi.org\/10.1080\/21645515.2017.1323604","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"2_CR64","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1128\/JVI.73.7.5934-5944.1999","volume":"73","author":"Z Mikloska","year":"1999","unstructured":"Mikloska Z, Sanna PP, Cunningham AL (1999) Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro. J Virol 73(7):5934\u20135944","journal-title":"J Virol"},{"issue":"3","key":"2_CR65","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1016\/s2214-109x(16)30362-x","volume":"5","author":"KJ Looker","year":"2017","unstructured":"Looker KJ, Magaret AS, May MT et al (2017) First estimates of the global and regional incidence of neonatal herpes infection. Lancet Glob Health 5(3):e300\u2013e309. https:\/\/doi.org\/10.1016\/s2214-109x(16)30362-x","journal-title":"Lancet Glob Health"},{"issue":"5","key":"2_CR66","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1056\/nejm198701293160503","volume":"316","author":"CG Prober","year":"1987","unstructured":"Prober CG, Sullender WM, Yasukawa LL et al (1987) Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med 316(5):240\u2013244. https:\/\/doi.org\/10.1056\/nejm198701293160503","journal-title":"N Engl J Med"},{"issue":"2","key":"2_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/jama.289.2.203","volume":"289","author":"ZA Brown","year":"2003","unstructured":"Brown ZA, Wald A, Morrow RA et al (2003) Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 289(2):203\u2013209","journal-title":"JAMA"},{"issue":"4","key":"2_CR68","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/pch\/19.4.201","volume":"19","author":"UD Allen","year":"2014","unstructured":"Allen UD, Robinson JL (2014) Prevention and management of neonatal herpes simplex virus infections. Paediatr Child Health 19(4):201\u2013212","journal-title":"Paediatr Child Health"},{"key":"2_CR69","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0002-9378(16)36111-7","volume":"82","author":"J Dancis","year":"1961","unstructured":"Dancis J, Lind J, Oratz M et al (1961) Placental transfer of proteins in human gestation. Am J Obstet Gynecol 82:167\u2013171","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"2_CR70","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1086\/340572","volume":"185","author":"IA Evans","year":"2002","unstructured":"Evans IA, Jones CA (2002) Maternal immunization with a herpes simplex virus type 2 replication-defective virus reduces visceral dissemination but not lethal encephalitis in newborn mice after oral challenge. J Infect Dis 185(11):1550\u20131560. https:\/\/doi.org\/10.1086\/340572","journal-title":"J Infect Dis"},{"key":"2_CR71","doi-asserted-by":"publisher","unstructured":"Jiang Y, Patel CD, Manivanh R et al (2017) Maternal antiviral immunoglobulin accumulates in neural tissue of neonates to prevent HSV neurological disease. mBio 8(4). https:\/\/doi.org\/10.1128\/mBio.00678-17","DOI":"10.1128\/mBio.00678-17"},{"issue":"Suppl 1","key":"2_CR72","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1093\/ofid\/ofx162.056","volume":"4","author":"C Kao","year":"2017","unstructured":"Kao C, Burn C, Jacobs WR Jr et al (2017) Maternal immunization with a single-cycle herpes simplex virus (HSV) candidate vaccine, \u0394gD-2, protects neonatal mice from lethal viral challenge. Open Forum Infect Dis 4(Suppl 1):S22. https:\/\/doi.org\/10.1093\/ofid\/ofx162.056","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"2_CR73","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/s1473-3099(17)30229-3","volume":"17","author":"A Marchant","year":"2017","unstructured":"Marchant A, Sadarangani M, Garand M et al (2017) Maternal immunisation: collaborating with mother nature. Lancet Infect Dis 17(7):e197\u2013e208. https:\/\/doi.org\/10.1016\/s1473-3099(17)30229-3","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2_CR74","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1084\/jem.184.2.747","volume":"184","author":"M Cella","year":"1996","unstructured":"Cella M, Scheidegger D, Palmer-Lehmann K et al (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184(2):747\u2013752","journal-title":"J Exp Med"},{"issue":"8","key":"2_CR75","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/ni.1899","volume":"11","author":"KM Murphy","year":"2010","unstructured":"Murphy KM, Stockinger B (2010) Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol 11(8):674\u2013680. https:\/\/doi.org\/10.1038\/ni.1899","journal-title":"Nat Immunol"},{"issue":"13","key":"2_CR76","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1084\/jem.20082039","volume":"205","author":"N Iijima","year":"2008","unstructured":"Iijima N, Linehan MM, Zamora M et al (2008) Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J Exp Med 205(13):3041\u20133052. https:\/\/doi.org\/10.1084\/jem.20082039","journal-title":"J Exp Med"},{"key":"2_CR77","doi-asserted-by":"publisher","unstructured":"Bourne N, Perry CL, Banasik BN et al (2019) Increased frequency of virus shedding by herpes simplex virus 2-infected guinea pigs in the absence of CD4(+) T lymphocytes. J Virol 93(4). https:\/\/doi.org\/10.1128\/jvi.01721-18","DOI":"10.1128\/jvi.01721-18"},{"issue":"4","key":"2_CR78","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s13365-013-0189-3","volume":"19","author":"KP Egan","year":"2013","unstructured":"Egan KP, Wu S, Wigdahl B et al (2013) Immunological control of herpes simplex virus infections. J Neurovirol 19(4):328\u2013345. https:\/\/doi.org\/10.1007\/s13365-013-0189-3","journal-title":"J Neurovirol"},{"issue":"4","key":"2_CR79","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.coviro.2013.04.004","volume":"3","author":"WJ Ouwendijk","year":"2013","unstructured":"Ouwendijk WJ, Laing KJ, Verjans GM et al (2013) T-cell immunity to human alphaherpesviruses. Curr Opin Virol 3(4):452\u2013460. https:\/\/doi.org\/10.1016\/j.coviro.2013.04.004","journal-title":"Curr Opin Virol"},{"issue":"8","key":"2_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003547","volume":"9","author":"M Velzen van","year":"2013","unstructured":"van Velzen M, Jing L, Osterhaus AD et al (2013) Local CD4 and CD8 T-cell reactivity to HSV-1 antigens documents broad viral protein expression and immune competence in latently infected human trigeminal ganglia. PLoS Pathog 9(8):e1003547. https:\/\/doi.org\/10.1371\/journal.ppat.1003547","journal-title":"PLoS Pathog"},{"issue":"16","key":"2_CR81","doi-asserted-by":"publisher","first-page":"10339","DOI":"10.1128\/jvi.79.16.10339-10347.2005","volume":"79","author":"V Decman","year":"2005","unstructured":"Decman V, Kinchington PR, Harvey SA et al (2005) Gamma interferon can block herpes simplex virus type 1 reactivation from latency, even in the presence of late gene expression. J Virol 79(16):10339\u201310347. https:\/\/doi.org\/10.1128\/jvi.79.16.10339-10347.2005","journal-title":"J Virol"},{"issue":"5899","key":"2_CR82","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.1164164","volume":"322","author":"JE Knickelbein","year":"2008","unstructured":"Knickelbein JE, Khanna KM, Yee MB et al (2008) Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 322(5899):268\u2013271. https:\/\/doi.org\/10.1126\/science.1164164","journal-title":"Science"},{"issue":"7272","key":"2_CR83","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nature08511","volume":"462","author":"Y Nakanishi","year":"2009","unstructured":"Nakanishi Y, Lu B, Gerard C et al (2009) CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462(7272):510\u2013513. https:\/\/doi.org\/10.1038\/nature08511","journal-title":"Nature"},{"issue":"8","key":"2_CR84","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nm.2006","volume":"15","author":"J Zhu","year":"2009","unstructured":"Zhu J, Hladik F, Woodward A et al (2009) Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 15(8):886\u2013892. https:\/\/doi.org\/10.1038\/nm.2006","journal-title":"Nat Med"},{"issue":"7450","key":"2_CR85","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nature12110","volume":"497","author":"J Zhu","year":"2013","unstructured":"Zhu J, Peng T, Johnston C et al (2013) Immune surveillance by CD8alphaalpha+ skin-resident T cells in human herpes virus infection. Nature 497(7450):494\u2013497. https:\/\/doi.org\/10.1038\/nature12110","journal-title":"Nature"},{"issue":"3","key":"2_CR86","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1084\/jem.20061792","volume":"204","author":"J Zhu","year":"2007","unstructured":"Zhu J, Koelle DM, Cao J et al (2007) Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 204(3):595\u2013603. https:\/\/doi.org\/10.1084\/jem.20061792","journal-title":"J Exp Med"},{"issue":"5","key":"2_CR87","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/mi.2016.118","volume":"10","author":"CM Posavad","year":"2017","unstructured":"Posavad CM, Zhao L, Dong L et al (2017) Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. Mucosal Immunol 10(5):1259\u20131269. https:\/\/doi.org\/10.1038\/mi.2016.118","journal-title":"Mucosal Immunol"},{"issue":"19","key":"2_CR88","doi-asserted-by":"publisher","first-page":"10587","DOI":"10.1128\/jvi.01237-12","volume":"86","author":"T Peng","year":"2012","unstructured":"Peng T, Zhu J, Phasouk K et al (2012) An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection. J Virol 86(19):10587\u201310596. https:\/\/doi.org\/10.1128\/jvi.01237-12","journal-title":"J Virol"},{"issue":"5","key":"2_CR89","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.4049\/jimmunol.1800471","volume":"201","author":"JT Schiffer","year":"2018","unstructured":"Schiffer JT, Swan DA, Roychoudhury P et al (2018) A fixed spatial structure of CD8(+) T cells in tissue during chronic HSV-2 infection. J Immunol 201(5):1522\u20131535. https:\/\/doi.org\/10.4049\/jimmunol.1800471","journal-title":"J Immunol"},{"issue":"16","key":"2_CR90","doi-asserted-by":"publisher","first-page":"8271","DOI":"10.1128\/jvi.00656-06","volume":"80","author":"GA Diaz","year":"2006","unstructured":"Diaz GA, Koelle DM (2006) Human CD4+ CD25 high cells suppress proliferative memory lymphocyte responses to herpes simplex virus type 2. J Virol 80(16):8271\u20138273. https:\/\/doi.org\/10.1128\/jvi.00656-06","journal-title":"J Virol"},{"issue":"3","key":"2_CR91","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.4049\/jimmunol.180.3.1556","volume":"180","author":"MA Fernandez","year":"2008","unstructured":"Fernandez MA, Puttur FK, Wang YM et al (2008) T regulatory cells contribute to the attenuated primary CD8+ and CD4+ T cell responses to herpes simplex virus type 2 in neonatal mice. J Immunol 180(3):1556\u20131564","journal-title":"J Immunol"},{"issue":"1\u20132","key":"2_CR92","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.virol.2013.08.027","volume":"447","author":"MA Fernandez","year":"2013","unstructured":"Fernandez MA, Yu U, Zhang G et al (2013) Treg depletion attenuates the severity of skin disease from ganglionic spread after HSV-2 flank infection. Virology 447(1\u20132):9\u201320. https:\/\/doi.org\/10.1016\/j.virol.2013.08.027","journal-title":"Virology"},{"issue":"1","key":"2_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/jiw091","volume":"214","author":"N Milman","year":"2016","unstructured":"Milman N, Zhu J, Johnston C et al (2016) In situ detection of regulatory T cells in human genital herpes simplex virus type 2 (HSV-2) reactivation and their influence on spontaneous HSV-2 reactivation. J Infect Dis 214(1):23\u201331. https:\/\/doi.org\/10.1093\/infdis\/jiw091","journal-title":"J Infect Dis"},{"issue":"1","key":"2_CR94","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/1523-1747.ep12873333","volume":"94","author":"JD Bos","year":"1990","unstructured":"Bos JD, Teunissen MB, Cairo I et al (1990) T-cell receptor gamma delta bearing cells in normal human skin. J Invest Dermatol 94(1):37\u201342","journal-title":"J Invest Dermatol"},{"issue":"11","key":"2_CR95","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1084\/jem.185.11.1969","volume":"185","author":"R Sciammas","year":"1997","unstructured":"Sciammas R, Kodukula P, Tang Q et al (1997) T cell receptor-gamma\/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis. J Exp Med 185(11):1969\u20131975","journal-title":"J Exp Med"},{"issue":"1","key":"2_CR96","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4049\/jimmunol.0904106","volume":"185","author":"FK Puttur","year":"2010","unstructured":"Puttur FK, Fernandez MA, White R et al (2010) Herpes simplex virus infects skin gamma delta T cells before Langerhans cells and impedes migration of infected Langerhans cells by inducing apoptosis and blocking E-cadherin downregulation. J Immunol 185(1):477\u2013487. https:\/\/doi.org\/10.4049\/jimmunol.0904106","journal-title":"J Immunol"},{"key":"2_CR97","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1146\/annurev-immunol-051116-052215","volume":"35","author":"SW Kashem","year":"2017","unstructured":"Kashem SW, Haniffa M, Kaplan DH (2017) Antigen-presenting cells in the skin. Annu Rev Immunol 35:469\u2013499. https:\/\/doi.org\/10.1146\/annurev-immunol-051116-052215","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"2_CR98","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.4049\/jimmunol.174.4.2220","volume":"174","author":"L Bosnjak","year":"2005","unstructured":"Bosnjak L, Miranda-Saksena M, Koelle DM et al (2005) Herpes simplex virus infection of human dendritic cells induces apoptosis and allows cross-presentation via uninfected dendritic cells. J Immunol 174(4):2220\u20132227","journal-title":"J Immunol"},{"issue":"13","key":"2_CR99","doi-asserted-by":"publisher","first-page":"5958","DOI":"10.1128\/jvi.75.13.5958-5964.2001","volume":"75","author":"Z Mikloska","year":"2001","unstructured":"Mikloska Z, Bosnjak L, Cunningham AL (2001) Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1. J Virol 75(13):5958\u20135964. https:\/\/doi.org\/10.1128\/jvi.75.13.5958-5964.2001","journal-title":"J Virol"},{"issue":"3\u20134","key":"2_CR100","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF01314292","volume":"91","author":"E Sprecher","year":"1986","unstructured":"Sprecher E, Becker Y (1986) Skin Langerhans cells play an essential role in the defense against HSV-1 infection. Arch Virol 91(3\u20134):341\u2013349","journal-title":"Arch Virol"},{"issue":"5641","key":"2_CR101","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1126\/science.1087576","volume":"301","author":"RS Allan","year":"2003","unstructured":"Allan RS, Smith CM, Belz GT et al (2003) Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 301(5641):1925\u20131928. https:\/\/doi.org\/10.1126\/science.1087576","journal-title":"Science"},{"issue":"5","key":"2_CR102","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/ni.1724","volume":"10","author":"S Bedoui","year":"2009","unstructured":"Bedoui S, Whitney PG, Waithman J et al (2009) Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol 10(5):488\u2013495. https:\/\/doi.org\/10.1038\/ni.1724","journal-title":"Nat Immunol"},{"issue":"2","key":"2_CR103","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1084\/jem.20021109","volume":"197","author":"X Zhao","year":"2003","unstructured":"Zhao X, Deak E, Soderberg K et al (2003) Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 197(2):153\u2013162","journal-title":"J Exp Med"},{"issue":"4","key":"2_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004812","volume":"11","author":"M Kim","year":"2015","unstructured":"Kim M, Truong NR, James V et al (2015) Relay of herpes simplex virus between Langerhans cells and dermal dendritic cells in human skin. PLoS Pathog 11(4):e1004812. https:\/\/doi.org\/10.1371\/journal.ppat.1004812","journal-title":"PLoS Pathog"},{"issue":"8","key":"2_CR105","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nri3712","volume":"14","author":"M Guilliams","year":"2014","unstructured":"Guilliams M, Ginhoux F, Jakubzick C et al (2014) Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol 14(8):571\u2013578. https:\/\/doi.org\/10.1038\/nri3712","journal-title":"Nat Rev Immunol"},{"key":"2_CR106","doi-asserted-by":"publisher","first-page":"98","DOI":"10.12688\/f1000research.9997.1","volume":"6","author":"D Theisen","year":"2017","unstructured":"Theisen D, Murphy K (2017) The role of cDC1s in vivo: CD8 T cell priming through cross-presentation. F1000Research 6:98. https:\/\/doi.org\/10.12688\/f1000research.9997.1","journal-title":"F1000Research"},{"issue":"11","key":"2_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143519","volume":"10","author":"CM Fehres","year":"2015","unstructured":"Fehres CM, Bruijns SC, Sotthewes BN et al (2015) Phenotypic and functional properties of human steady state CD14+ and CD1a+ antigen presenting cells and epidermal Langerhans cells. PLoS One 10(11):e0143519. https:\/\/doi.org\/10.1371\/journal.pone.0143519","journal-title":"PLoS One"},{"issue":"1","key":"2_CR108","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.immuni.2012.04.012","volume":"37","author":"M Haniffa","year":"2012","unstructured":"Haniffa M, Shin A, Bigley V et al (2012) Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 37(1):60\u201373. https:\/\/doi.org\/10.1016\/j.immuni.2012.04.012","journal-title":"Immunity"},{"issue":"3","key":"2_CR109","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.immuni.2014.08.006","volume":"41","author":"N McGovern","year":"2014","unstructured":"McGovern N, Schlitzer A, Gunawan M et al (2014) Human dermal CD14(+) cells are a transient population of monocyte-derived macrophages. Immunity 41(3):465\u2013477. https:\/\/doi.org\/10.1016\/j.immuni.2014.08.006","journal-title":"Immunity"},{"issue":"18","key":"2_CR110","doi-asserted-by":"publisher","first-page":"9213","DOI":"10.1128\/jvi.01213-15","volume":"89","author":"TM Cairns","year":"2015","unstructured":"Cairns TM, Huang ZY, Gallagher JR et al (2015) Patient-specific neutralizing antibody responses to herpes simplex virus are attributed to epitopes on gD, gB, or both and can be type specific. J Virol 89(18):9213\u20139231. https:\/\/doi.org\/10.1128\/jvi.01213-15","journal-title":"J Virol"},{"issue":"21","key":"2_CR111","doi-asserted-by":"publisher","first-page":"12612","DOI":"10.1128\/jvi.01930-14","volume":"88","author":"TM Cairns","year":"2014","unstructured":"Cairns TM, Huang ZY, Whitbeck JC et al (2014) Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans. J Virol 88(21):12612\u201312622. https:\/\/doi.org\/10.1128\/jvi.01930-14","journal-title":"J Virol"},{"issue":"4693","key":"2_CR112","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1126\/science.2983428","volume":"227","author":"PW Berman","year":"1985","unstructured":"Berman PW, Gregory T, Crase D et al (1985) Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science 227(4693):1490\u20131492","journal-title":"Science"},{"issue":"2","key":"2_CR113","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/JVI.53.2.634-644.1985","volume":"53","author":"RJ Eisenberg","year":"1985","unstructured":"Eisenberg RJ, Long D, Ponce de Leon M et al (1985) Localization of epitopes of herpes simplex virus type 1 glycoprotein D. J Virol 53(2):634\u2013644","journal-title":"J Virol"},{"issue":"10","key":"2_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109890","volume":"9","author":"BA Stanfield","year":"2014","unstructured":"Stanfield BA, Stahl J, Chouljenko VN et al (2014) A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains. PLoS One 9(10):e109890. https:\/\/doi.org\/10.1371\/journal.pone.0109890","journal-title":"PLoS One"},{"issue":"5","key":"2_CR115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007095","volume":"14","author":"LM Hook","year":"2018","unstructured":"Hook LM, Cairns TM, Awasthi S et al (2018) Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs. PLoS Pathog 14(5):e1007095. https:\/\/doi.org\/10.1371\/journal.ppat.1007095","journal-title":"PLoS Pathog"},{"issue":"Suppl 1","key":"2_CR116","doi-asserted-by":"publisher","first-page":"S415","DOI":"10.1093\/ofid\/ofx163.1041","volume":"4","author":"L Dropulic","year":"2017","unstructured":"Dropulic L, Wang K, Oestreich M et al (2017) A replication-defective herpes simplex virus (HSV)-2 vaccine, HSV529, is safe and well-tolerated in adults with or without HSV infection and induces significant HSV-2-specific antibody responses in HSV seronegative individuals. Open Forum Infect Dis 4(Suppl 1):S415\u2013S416. https:\/\/doi.org\/10.1093\/ofid\/ofx163.1041","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"2_CR117","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/infdis\/jix628","volume":"217","author":"C Burn","year":"2018","unstructured":"Burn C, Ramsey N, Garforth SJ et al (2018) A herpes simplex virus (HSV)-2 single-cycle candidate vaccine deleted in glycoprotein D protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2. J Infect Dis 217(5):754\u2013758. https:\/\/doi.org\/10.1093\/infdis\/jix628","journal-title":"J Infect Dis"},{"key":"2_CR118","doi-asserted-by":"publisher","unstructured":"Petro C, Gonzalez PA, Cheshenko N et al (2015) Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. eLife 4. https:\/\/doi.org\/10.7554\/eLife.06054","DOI":"10.7554\/eLife.06054"},{"key":"2_CR119","doi-asserted-by":"publisher","unstructured":"Petro CD, Weinrick B, Khajoueinejad N et al (2016) HSV-2 DeltagD elicits FcgammaR-effector antibodies that protect against clinical isolates. JCI Insight 1(12). https:\/\/doi.org\/10.1172\/jci.insight.88529","DOI":"10.1172\/jci.insight.88529"},{"issue":"4","key":"2_CR120","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/infdis\/161.4.653","volume":"161","author":"GJ Mertz","year":"1990","unstructured":"Mertz GJ, Ashley R, Burke RL et al (1990) Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 161(4):653\u2013660","journal-title":"J Infect Dis"},{"issue":"1","key":"2_CR121","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1086\/515590","volume":"178","author":"SS Terhune","year":"1998","unstructured":"Terhune SS, Coleman KT, Sekulovich R et al (1998) Limited variability of glycoprotein gene sequences and neutralizing targets in herpes simplex virus type 2 isolates and stability on passage in cell culture. J Infect Dis 178(1):8\u201315","journal-title":"J Infect Dis"},{"issue":"23","key":"2_CR122","doi-asserted-by":"publisher","first-page":"11422","DOI":"10.1128\/JVI.74.23.11422-11425.2000","volume":"74","author":"DM Koelle","year":"2000","unstructured":"Koelle DM, Schomogyi M, McClurkan C et al (2000) CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins. J Virol 74(23):11422\u201311425","journal-title":"J Virol"},{"issue":"9","key":"2_CR123","doi-asserted-by":"publisher","first-page":"6604","DOI":"10.4049\/jimmunol.181.9.6604","volume":"181","author":"M Kim","year":"2008","unstructured":"Kim M, Taylor J, Sidney J et al (2008) Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J Immunol 181(9):6604\u20136615","journal-title":"J Immunol"},{"issue":"10","key":"2_CR124","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.4049\/jimmunol.164.10.5167","volume":"164","author":"Z Mikloska","year":"2000","unstructured":"Mikloska Z, Ruckholdt M, Ghadiminejad I et al (2000) Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J Immunol 164(10):5167\u20135176","journal-title":"J Immunol"},{"issue":"11","key":"2_CR125","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1128\/JVI.02659-05","volume":"80","author":"N Hosken","year":"2006","unstructured":"Hosken N, McGowan P, Meier A et al (2006) Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 80(11):5509\u20135515. https:\/\/doi.org\/10.1128\/JVI.02659-05","journal-title":"J Virol"},{"issue":"5","key":"2_CR126","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.4049\/jimmunol.1502366","volume":"196","author":"L Jing","year":"2016","unstructured":"Jing L, Laing KJ, Dong L et al (2016) Extensive CD4 and CD8 T cell cross-reactivity between Alphaherpesviruses. J Immunol 196(5):2205\u20132218. https:\/\/doi.org\/10.4049\/jimmunol.1502366","journal-title":"J Immunol"},{"issue":"9","key":"2_CR127","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1158\/1535-7163.Mct-17-0071","volume":"16","author":"B Porchia","year":"2017","unstructured":"Porchia B, Moreno ACR, Ramos RN et al (2017) Herpes simplex virus glycoprotein D targets a specific dendritic cell subset and improves the performance of vaccines to human papillomavirus-associated tumors. Mol Cancer Ther 16(9):1922\u20131933. https:\/\/doi.org\/10.1158\/1535-7163.Mct-17-0071","journal-title":"Mol Cancer Ther"},{"key":"2_CR128","unstructured":"Ford E, Li A, Dong L, et al. (2018) Expansion of the tissue based T-cell receptor repertoire is distinct from the PBMC response after immunotherapeutic HSV-2 vaccine. Paper presented at the International Herpesvirus Workshop, Vancouver, BC"},{"issue":"1","key":"2_CR129","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1128\/jvi.01845-15","volume":"90","author":"K Wang","year":"2016","unstructured":"Wang K, Goodman KN, Li DY et al (2016) A herpes simplex virus 2 (HSV-2) gD mutant impaired for neural tropism is superior to an HSV-2 gD subunit vaccine to protect animals from challenge with HSV-2. J Virol 90(1):562\u2013574. https:\/\/doi.org\/10.1128\/jvi.01845-15","journal-title":"J Virol"},{"issue":"7424","key":"2_CR130","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature11522","volume":"491","author":"H Shin","year":"2012","unstructured":"Shin H, Iwasaki A (2012) A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491(7424):463\u2013467. https:\/\/doi.org\/10.1038\/nature11522","journal-title":"Nature"},{"key":"2_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13346","volume":"7","author":"H Shin","year":"2016","unstructured":"Shin H, Kumamoto Y, Gopinath S et al (2016) CD301b+ dendritic cells stimulate tissue-resident memory CD8+ T cells to protect against genital HSV-2. Nat Commun 7:13346. https:\/\/doi.org\/10.1038\/ncomms13346","journal-title":"Nat Commun"},{"issue":"37","key":"2_CR132","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1016\/j.vaccine.2017.07.073","volume":"35","author":"M Ahmed","year":"2017","unstructured":"Ahmed M, Smith DM, Hamouda T et al (2017) A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice. Vaccine 35(37):4983\u20134989. https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.073","journal-title":"Vaccine"},{"issue":"12","key":"2_CR133","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1080\/21645515.2015.1075680","volume":"11","author":"JJ O\u2019Konek","year":"2015","unstructured":"O\u2019Konek JJ, Makidon PE, Landers JJ et al (2015) Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats. Hum Vaccin Immunother 11(12):2904\u20132912. https:\/\/doi.org\/10.1080\/21645515.2015.1075680","journal-title":"Hum Vaccin Immunother"},{"key":"2_CR134","unstructured":"Bluewillow Biologics (2018) HSV-2 vaccine. Bluewillow Biologics. http:\/\/www.bluewillow.com\/vaccine-pipeline\/hsv-2-vaccine\/"},{"issue":"2","key":"2_CR135","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/mi.2008.81","volume":"2","author":"X Zhang","year":"2009","unstructured":"Zhang X, Chentoufi AA, Dasgupta G et al (2009) A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol 2(2):129\u2013143. https:\/\/doi.org\/10.1038\/mi.2008.81","journal-title":"Mucosal Immunol"},{"issue":"9","key":"2_CR136","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.4049\/jimmunol.1201121","volume":"189","author":"X Zhang","year":"2012","unstructured":"Zhang X, Dervillez X, Chentoufi AA et al (2012) Targeting the genital tract mucosa with a lipopeptide\/recombinant adenovirus prime\/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88. J Immunol 189(9):4496\u20134509. https:\/\/doi.org\/10.4049\/jimmunol.1201121","journal-title":"J Immunol"},{"issue":"5","key":"2_CR137","first-page":"1021","volume":"9","author":"Q He","year":"2002","unstructured":"He Q, Mitchell A, Morcol T et al (2002) Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol 9(5):1021\u20131024","journal-title":"Clin Diagn Lab Immunol"},{"issue":"4","key":"2_CR138","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nri2510","volume":"9","author":"P Marrack","year":"2009","unstructured":"Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9(4):287\u2013293. https:\/\/doi.org\/10.1038\/nri2510","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2_CR139","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/vaccines3020320","volume":"3","author":"A Pasquale Di","year":"2015","unstructured":"Di Pasquale A, Preiss S, Tavares Da Silva F et al (2015) Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccine 3(2):320\u2013343. https:\/\/doi.org\/10.3390\/vaccines3020320","journal-title":"Vaccine"},{"key":"2_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13324","volume":"7","author":"MH Brok den","year":"2016","unstructured":"den Brok MH, Bull C, Wassink M et al (2016) Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nat Commun 7:13324. https:\/\/doi.org\/10.1038\/ncomms13324","journal-title":"Nat Commun"},{"issue":"44","key":"2_CR141","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1016\/j.vaccine.2016.09.001","volume":"34","author":"JB Flechtner","year":"2016","unstructured":"Flechtner JB, Long D, Larson S et al (2016) Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1\/2a trial. Vaccine 34(44):5314\u20135320. https:\/\/doi.org\/10.1016\/j.vaccine.2016.09.001","journal-title":"Vaccine"},{"key":"2_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00159","volume":"5","author":"G Ferlazzo","year":"2014","unstructured":"Ferlazzo G, Morandi B (2014) Cross-talks between natural killer cells and distinct subsets of dendritic cells. Front Immunol 5:159. https:\/\/doi.org\/10.3389\/fimmu.2014.00159","journal-title":"Front Immunol"},{"issue":"5","key":"2_CR143","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/ijc.29087","volume":"136","author":"F Deauvieau","year":"2015","unstructured":"Deauvieau F, Ollion V, Doffin AC et al (2015) Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. Int J Cancer 136(5):1085\u20131094. https:\/\/doi.org\/10.1002\/ijc.29087","journal-title":"Int J Cancer"},{"issue":"6002","key":"2_CR144","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1126\/science.330.6002.304","volume":"330","author":"J Cohen","year":"2010","unstructured":"Cohen J (2010) Immunology. Painful failure of promising genital herpes vaccine. Science 330(6002):304","journal-title":"Science"},{"issue":"6","key":"2_CR145","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/infdis\/jix004","volume":"215","author":"DI Bernstein","year":"2017","unstructured":"Bernstein DI, Wald A, Warren T et al (2017) Therapeutic vaccine for genital herpes simplex virus-2 infection: findings from a randomized trial. J Infect Dis 215(6):856\u2013864","journal-title":"J Infect Dis"},{"key":"2_CR146","unstructured":"Genocea (2017) Genocea announces strategic shift to immuno oncology and the development of neoantigen cancer vaccines"},{"issue":"12","key":"2_CR147","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/infdis\/jiy415","volume":"218","author":"N Wagoner Van","year":"2018","unstructured":"Van Wagoner N, Fife K, Leone PA et al (2018) Effects of different doses of GEN-003, a therapeutic vaccine for genital herpes simplex virus-2, on viral shedding and lesions: results of a randomized placebo-controlled trial. J Infect Dis 218(12):1890\u20131899","journal-title":"J Infect Dis"},{"issue":"47","key":"2_CR148","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1016\/j.vaccine.2011.09.046","volume":"29","author":"A Wald","year":"2011","unstructured":"Wald A, Koelle DM, Fife K et al (2011) Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 29(47):8520\u20138529","journal-title":"Vaccine"},{"key":"2_CR149","unstructured":"Agenus (2014) Agenus vaccine shows significant reduction in viral burden after herpv generated immune activation [online]. https:\/\/investor.agenusbio.com\/2014-06-26-Agenus-Vaccine-Shows-Significant-Reduction-in-Viral-Burden-after-HerpV-Generated-Immune-Activation"},{"issue":"49","key":"2_CR150","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.1016\/j.vaccine.2012.09.057","volume":"30","author":"RL Veselenak","year":"2012","unstructured":"Veselenak RL, Shlapobersky M, Pyles RB et al (2012) A Vaxfectin((R))-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 30(49):7046\u20137051","journal-title":"Vaccine"},{"key":"2_CR151","unstructured":"Vical (2018) Vical reports phase 2 trial of HSV-2 therapeutic vaccine did not meet primary endpoint. Vical"},{"key":"2_CR152","unstructured":"Admedus (2017) Admedus hsv 2 phase iia results. Admedus"},{"issue":"12","key":"2_CR153","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1080\/21645515.2016.1221872","volume":"12","author":"JL Dutton","year":"2016","unstructured":"Dutton JL, Woo WP, Chandra J et al (2016) An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1. Hum Vaccin Immunother 12(12):3079\u20133088","journal-title":"Hum Vaccin Immunother"},{"key":"2_CR154","unstructured":"Proactive Investors (2017) Admedus meets primary endpoint for herpes vaccine study [online]. https:\/\/www.proactiveinvestors.com.au\/companies\/news\/177275\/admedus-meets-primary-endpoint-for-herpes-vaccine-study-177275.html"},{"key":"2_CR155","unstructured":"Bluewillow Biologics (2017) Nanobio receives sbir grant for genital herpes vaccine [online]. http:\/\/www.bluewillow.com\/nanobio-receives-sbir-grant-for-genital-herpes-vaccine\/"},{"issue":"15","key":"2_CR156","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.1128\/JVI.01130-14","volume":"88","author":"S Awasthi","year":"2014","unstructured":"Awasthi S, Huang J, Shaw C et al (2014) Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes. J Virol 88(15):8421\u20138432","journal-title":"J Virol"},{"issue":"1","key":"2_CR157","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.vaccine.2015.10.137","volume":"34","author":"JM Odegard","year":"2016","unstructured":"Odegard JM, Flynn PA, Campbell DJ et al (2016) A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Vaccine 34(1):101\u2013109","journal-title":"Vaccine"},{"key":"2_CR158","unstructured":"NIH (2018) HSV vaccine in hsv-2 seropositive adults [online]. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02571166?view=record"},{"issue":"3","key":"2_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017748","volume":"6","author":"WP Halford","year":"2011","unstructured":"Halford WP, Puschel R, Gershburg E et al (2011) A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 6(3):e17748","journal-title":"PLoS One"},{"issue":"4","key":"2_CR160","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.vaccine.2016.12.018","volume":"35","author":"BA Stanfield","year":"2017","unstructured":"Stanfield BA, Pahar B, Chouljenko VN et al (2017) Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies. Vaccine 35(4):536\u2013543","journal-title":"Vaccine"},{"issue":"20","key":"2_CR161","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1016\/j.vaccine.2018.03.075","volume":"36","author":"BA Stanfield","year":"2018","unstructured":"Stanfield BA, Rider PJF, Caskey J et al (2018) Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses. Vaccine 36(20):2842\u20132849","journal-title":"Vaccine"},{"issue":"12","key":"2_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006741","volume":"13","author":"AL Richards","year":"2017","unstructured":"Richards AL, Sollars PJ, Pitts JD et al (2017) The pUL37 tegument protein guides alpha-herpesvirus retrograde axonal transport to promote neuroinvasion. PLoS Pathog 13(12):e1006741","journal-title":"PLoS Pathog"},{"key":"2_CR163","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fimmu.2019.00373","volume":"10","author":"NR Truong","year":"2019","unstructured":"Truong NR, Smith JB, Sandgren KJ et al (2019) Mechanisms of immune control of mucosal HSV infection: a guide to rational vaccine design. Front Immunol 10:373","journal-title":"Front Immunol"},{"issue":"7","key":"2_CR164","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/sti.2009.036103","volume":"85","author":"V Chohan","year":"2009","unstructured":"Chohan V, Baeten JM, Benki S et al (2009) A prospective study of risk factors for herpes simplex virus type 2 acquisition among high-risk HIV-1 seronegative women in Kenya. Sex Transm Infect 85(7):489\u2013492. https:\/\/doi.org\/10.1136\/sti.2009.036103","journal-title":"Sex Transm Infect"},{"issue":"1","key":"2_CR165","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.immuni.2016.12.013","volume":"46","author":"C Gosmann","year":"2017","unstructured":"Gosmann C, Anahtar MN, Handley SA et al (2017) Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity 46(1):29\u201337. https:\/\/doi.org\/10.1016\/j.immuni.2016.12.013","journal-title":"Immunity"},{"issue":"9","key":"2_CR166","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/qad.0000000000000646","volume":"29","author":"L Masese","year":"2015","unstructured":"Masese L, Baeten JM, Richardson BA et al (2015) Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. AIDS 29(9):1077\u20131085. https:\/\/doi.org\/10.1097\/qad.0000000000000646","journal-title":"AIDS"},{"issue":"7","key":"2_CR167","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/infdis\/jit634","volume":"209","author":"L Masese","year":"2014","unstructured":"Masese L, Baeten JM, Richardson BA et al (2014) Incident herpes simplex virus type 2 infection increases the risk of subsequent episodes of bacterial vaginosis. J Infect Dis 209(7):1023\u20131027. https:\/\/doi.org\/10.1093\/infdis\/jit634","journal-title":"J Infect Dis"}],"container-title":["Methods in Molecular Biology","Herpes Simplex Virus"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-9814-2_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T22:14:33Z","timestamp":1611526473000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-9814-2_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"ISBN":["9781493998135","9781493998142"],"references-count":167,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-9814-2_2","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"assertion":[{"value":"16 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}